These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

361 related items for PubMed ID: 21242747

  • 1. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response.
    Chaparro M, Panes J, García V, Mañosa M, Esteve M, Merino O, Andreu M, Gutierrez A, Gomollón F, Cabriada JL, Montoro MA, Mendoza JL, Nos P, Gisbert JP.
    J Clin Gastroenterol; 2011 Feb; 45(2):113-8. PubMed ID: 21242747
    [Abstract] [Full Text] [Related]

  • 2. [Treatment of Crohn's disease by infliximab. About 20 cases].
    Serghini M, Karoui S, Meknini M, Matri S, Kallel L, Fekih M, Boubaker J, Filali A.
    Tunis Med; 2009 Sep; 87(9):579-82. PubMed ID: 20180377
    [Abstract] [Full Text] [Related]

  • 3. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review.
    Gisbert JP, Panés J.
    Am J Gastroenterol; 2009 Mar; 104(3):760-7. PubMed ID: 19174781
    [Abstract] [Full Text] [Related]

  • 4. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
    Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R, REACH Study Group.
    Gastroenterology; 2007 Mar; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
    [Abstract] [Full Text] [Related]

  • 5. The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab.
    Kopylov U, Mantzaris GJ, Katsanos KH, Reenaers C, Ellul P, Rahier JF, Israeli E, Lakatos PL, Fiorino G, Cesarini M, Tsianos EV, Louis E, Ben-Horin S.
    Aliment Pharmacol Ther; 2011 Feb; 33(3):349-57. PubMed ID: 21118397
    [Abstract] [Full Text] [Related]

  • 6. Timing infliximab therapy in pediatric Crohn's disease.
    Kirschner BS, Huo D.
    Gastroenterology; 2007 Mar; 132(3):1167-70. PubMed ID: 17383435
    [No Abstract] [Full Text] [Related]

  • 7. [Frequency and possible reasons for the loss of response to biological therapy in Crohn's disease after a one-year treatment period].
    Molnár T, Farkas K, Nyári T, Szepes Z, Nagy F, Kiss T, Wittmann T.
    Orv Hetil; 2011 Jun 12; 152(24):951-7. PubMed ID: 21609921
    [Abstract] [Full Text] [Related]

  • 8. Infliximab improves inflammation and anthropometric measures in pediatric Crohn's disease.
    Sinitsky DM, Lemberg DA, Leach ST, Bohane TD, Jackson R, Day AS.
    J Gastroenterol Hepatol; 2010 Apr 12; 25(4):810-6. PubMed ID: 20492339
    [Abstract] [Full Text] [Related]

  • 9. Short-term study of infliximab treatment for Crohn's disease in China.
    Zheng JJ, Zhi P, Wang YM, Zhu F, Gu W, Xing YC, Zhou CL, Shen BW.
    J Dig Dis; 2011 Apr 12; 12(2):105-9. PubMed ID: 21401895
    [Abstract] [Full Text] [Related]

  • 10. [Treatment of Crohn's disease with anti-TNF alpha antibodies (infliximab): results of a multicentric and retrospective study].
    Doubremelle M, Bourreille A, Zerbib F, Heresbach D, Metman EH, Beau P, Gournay J, Galmiche JP.
    Gastroenterol Clin Biol; 2002 Nov 12; 26(11):973-9. PubMed ID: 12483127
    [Abstract] [Full Text] [Related]

  • 11. Clinical challenges and images in GI. Oral lichenoid reaction in a patient with Crohn's disease receiving infliximab.
    Moss AC, Treister NS, Marsee DK, Cheifetz AS.
    Gastroenterology; 2007 Feb 12; 132(2):488, 829. PubMed ID: 17261307
    [No Abstract] [Full Text] [Related]

  • 12. Adalimumab in patients with Crohn's disease--safety and efficacy in an open-label single centre study.
    Seiderer J, Brand S, Dambacher J, Pfennig S, Jürgens M, Göke B, Ochsenkühn T.
    Aliment Pharmacol Ther; 2007 Apr 01; 25(7):787-96. PubMed ID: 17373917
    [Abstract] [Full Text] [Related]

  • 13. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
    Sandborn WJ, Hanauer SB.
    Am J Gastroenterol; 2002 Dec 01; 97(12):2962-72. PubMed ID: 12492177
    [Abstract] [Full Text] [Related]

  • 14. Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland.
    Russo EA, Iacucci M, Lindsay JO, Campbell S, Hart A, Hamlin J, Orchard T, Arebi N, Nightingale J, Jacyna MR, Gabe SM, O'Connor M, Harris AW, O'Morain C, Ghosh S.
    Eur J Gastroenterol Hepatol; 2010 Mar 01; 22(3):334-9. PubMed ID: 19528808
    [Abstract] [Full Text] [Related]

  • 15. Long-term outcome of non-fistulizing (ulcers, stricture) perianal Crohn's disease in patients treated with infliximab.
    Bouguen G, Trouilloud I, Siproudhis L, Oussalah A, Bigard MA, Bretagne JF, Peyrin-Biroulet L.
    Aliment Pharmacol Ther; 2009 Oct 01; 30(7):749-56. PubMed ID: 19583709
    [Abstract] [Full Text] [Related]

  • 16. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study.
    Peyrin-Biroulet L, Laclotte C, Bigard MA.
    Aliment Pharmacol Ther; 2007 Mar 15; 25(6):675-80. PubMed ID: 17311600
    [Abstract] [Full Text] [Related]

  • 17. [Indications and results of infliximab in Crohn's disease].
    Karoui S, Boubaker J, Filali A.
    Tunis Med; 2004 Dec 15; 82(12):1057-63. PubMed ID: 15822505
    [Abstract] [Full Text] [Related]

  • 18. Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions.
    Duburque C, Lelong J, Iacob R, Seddik M, Desreumaux P, Fournier C, Wallaert B, Cortot A, Colombel JF.
    Aliment Pharmacol Ther; 2006 Sep 01; 24(5):851-8. PubMed ID: 16918890
    [Abstract] [Full Text] [Related]

  • 19. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
    Kugathasan S, Werlin SL, Martinez A, Rivera MT, Heikenen JB, Binion DG.
    Am J Gastroenterol; 2000 Nov 01; 95(11):3189-94. PubMed ID: 11095340
    [Abstract] [Full Text] [Related]

  • 20. Infliximab: new indication. Ulcerative colitis: caution is needed due to long-term risks.
    Prescrire Int; 2007 Oct 01; 16(91):194. PubMed ID: 17926832
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.